PALATIN TECHS INC 

$22.82
134
+$8.33+57.49% Friday 21:00

Statistics

Day High
12.21
Day Low
8.54
52W High
72.5
52W Low
1.75
Volume
26,630
Avg. Volume
17,621
Mkt Cap
40.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q1 2024
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Next
-2.86
-0.49
1.89
4.26
Expected EPS
-1.243333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-34.61MNet Income

Analyst Ratings

$60.00Average Price Target
The highest estimate is 60.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTNT. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen develops therapeutics in areas similar to Palatin, including reproductive health and cardiovascular diseases, making them direct competitors in the biopharmaceutical market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer competes with Palatin in the development of novel drugs, including treatments in sexual health, where Palatin has a significant focus.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly offers products in men's health and other areas that overlap with Palatin's focus, particularly in treatments for conditions like erectile dysfunction.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, with its broad range of pharmaceutical products, competes in the same therapeutic areas as Palatin, including women's health and hormonal therapies.
Merck
MRK
Mkt Cap214.76B
Merck operates in various healthcare segments that compete with Palatin, including the development of drugs for sexual health and cardiovascular diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis competes with Palatin in multiple areas, including cardiovascular and metabolic conditions, through its extensive research and development in these fields.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb's diverse range of pharmaceutical products in areas like cardiovascular diseases places it in competition with Palatin Technologies.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a presence in the sexual health market, making it a competitor to Palatin, especially in the development of treatments for related conditions.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca's work in cardiovascular and metabolic diseases competes with Palatin's research and development efforts in similar therapeutic areas.

About

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Show more...
CEO
Dr. Carl Spana Ph.D.
Employees
29
Country
GB

Listings

0 Comments

Share your thoughts

FAQ

What is PALATIN TECHS INC stock price today?
The current price of PTNT is $22.82 USD — it has increased by +57.49% in the past 24 hours. Watch PALATIN TECHS INC stock price performance more closely on the chart.
What is PALATIN TECHS INC stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange PALATIN TECHS INC stocks are traded under the ticker PTNT.
Is PALATIN TECHS INC stock price growing?
PTNT stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year PALATIN TECHS INC has showed a -10.51% decrease.
What is PALATIN TECHS INC market cap?
Today PALATIN TECHS INC has the market capitalization of 40.44M
When is the next PALATIN TECHS INC earnings date?
PALATIN TECHS INC is going to release the next earnings report on May 19, 2026.
What were PALATIN TECHS INC earnings last quarter?
PTNT earnings for the last quarter are -2.86 USD per share, whereas the estimation was -2.35 USD resulting in a -21.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PALATIN TECHS INC revenue for the last year?
PALATIN TECHS INC revenue for the last year amounts to 0 USD.
What is PALATIN TECHS INC net income for the last year?
PTNT net income for the last year is -34.61M USD.
How many employees does PALATIN TECHS INC have?
As of April 04, 2026, the company has 29 employees.
In which sector is PALATIN TECHS INC located?
PALATIN TECHS INC operates in the Industrials sector.
When did PALATIN TECHS INC complete a stock split?
The last stock split for PALATIN TECHS INC was on August 12, 2025 with a ratio of 1:50.
Where is PALATIN TECHS INC headquartered?
PALATIN TECHS INC is headquartered in Monmouth Junction, GB.